Top

Journal of Cutaneous Medicine and Surgery

Published in:

01-07-2003 | Case Report

Facial Lipoatrophy Following Systemic Lupus Erythematosus

Authors: Audrey Dupéré, Yves Poulin

Published in: Journal of Cutaneous Medicine and Surgery | Issue 3/2003

Abstract

Background: Acquired partial lipodystrophy is a rare disorder. An association with systemic lupus erythematosus has been reported. In these cases, an immunologic basis is suggested by the presence of C3 nephritic factor and hypocomplementemia. Objective: The following report presents the case of a woman who developed a rapid loss of facial subcutaneous fat a few months after complete spontaneous resolution of cutaneous lesions of lupus. Conclusion: Absence of C3NeF in this case suggests that other immunological factors may be involved in the pathogenesis.

Black, MM, Cunliffe, WJ 1998Lipodystrophy.Rook, AWilkinson, DSEbling, FJG eds. Textbook of Dermatology, 6th edBlackwell ScienceOxford24262431

Garg, A 2000Lipodystrophies.Am J Med108143152

Font, J, Herrero, C, Bosch, X, et al. 1990Systemic lupus erythemetosus in a patient with lipodystrophy.J Am Acad Dermatol22337340PubMed

Simpson, NB, Cunliffe, WJ, Davison, AM 1979Partial lipodystrophy, glomerulonephritis and hypocomplementaemia.Br J Dermatol1011112

Jasin, HE 1979Systemic lupus erythematosus, partial lipodystrophy and hypocomplementemia.J Rheumatol64350PubMed

Walport, MJ, Davies, KA, Botto, M, et al. 1994C3 nephritic factor and SLE: report of four cases and review of the literature.Q J Med87609615

Cronin, CC, Higgins, T, Molloy, M 1995Lupus, C3 nephritic factor and partial lipodystrophy.Q J Med88298299

Chartier, S, Buzzanga, JB, Paquin, F 1987Partial lipodystrophy associated with a type 3 form of membranoproliferative glomerulonephritis.J Am Acad Dermatol16201205PubMed

Gürbüz, O, Yücelten, D, Ergun, T, et al. 1995Partial lipodystrophy.Int J Dermatol343637PubMed

10.

Daha, MR, Fearon, DT, Austen, KF 1976C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase.J Immunol11617PubMed

11.

Wayte, J, Bird, G, Wilkinson, JD 1996The clinical significance of partial lipoatrophy and C3 hypocomplementaemia: a report of two cases.Clin Exp Dermatol21131134CrossRefPubMed

12.

Porter, WM, O’Gorman–Lalor, O, Lane, RJM, et al. 2000Barraquer–Simons lipodystrophy, Raynaud’s phenomenom and cutaneous vasculitis.Clin Exp Dermatol25277280CrossRefPubMed

13.

Commens, C, O’Neill, P, Walker, G 1990Dermatomyositis associated with multifocal lipoatrophy.J Am Acad Dermatol22966969PubMed

14.

Torrelo, A, Espana, A, Boixeda, P, et al. 1991Partial lipodystrophy and dermatomyositis.Arch Dermatol12718461847CrossRefPubMed

15.

Kavanagh, GM, Colaco, B, Kennedy, CTC 1993Juvenile dermatomyositis associated with partial lipoatrophy.J Am Acad Dermatol28348351PubMed

16.

Huemer, C, Kitson, H, Malleson, PN, et al. 2001Lipodystrophy in patients with juvenile dermatomyositis–evaluation of clinical and metabolic abnormalities.J Rheumatol28610615PubMed

17.

Pujol, RM, Domingo, P, Guiu, XM, et al. 2000HIV-1 protease inhibitor-associated partial lipodystrophy: clinicopathologic review of 14 cases.J Am Acad Dermatol42193198PubMed

18.

Perrot, H 1988Les lipoatrophies localisées.Ann Dermatol Venereol115523527PubMed

19.

Tan, EM, Cohen, AS, Fries, JF, et al. 1982The 1982 revised criteria for the classification of systemic lupus erythematosus.Arthritis Rheum2512711277PubMed

20.

Mathieson, PW, Wurzner, R, Oliveira, DBG, et al. 1993Complement-mediated adipocyte lysis by nephritic factor sera.J Exp Med17718271831PubMed

21.

Ledru, E, Christeff, N, Patey, O, et al. 2000Alteration of tumor necrosis factor-alpha T-cell homeostasis following potent antiretroviral therapy: contribution to the development of human immunodeficiency virus-associated lipodystrophy syndrome.Blood9531913198PubMed

22.

Mynarcik, DC, McNurlan, MA, Steigbigel, RT, et al. 2000Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy.J Acquir Immune Defic Syndr25312321CrossRefPubMed

23.

Pachman, LM, Liotta–Davis, MR, Hong, DK, et al. 2000TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications.Arthritis Rheum4323682377CrossRefPubMed

24.

Ducours, JL, Poizac, P, Ardanza, B, et al. 1991Barraquer–Simons syndrome and facial lipo-filling. A propos of a case.Rev Stomatol Chir Maxiliofac92105111

25.

Carruthers, A 2001Facial lipoatrophy.J Cutan Med Surg533PubMed

26.

Oral, EA, Simha, V, Ruiz, E, et al. 2002Leptin-replacement therapy for lipodystrophy.N EngI J Med346570578CrossRef

Title: Facial Lipoatrophy Following Systemic Lupus Erythematosus
Authors: Audrey Dupéré
Yves Poulin
Publication date: 01-07-2003
Publisher: Springer-Verlag
Published in: Journal of Cutaneous Medicine and Surgery / Issue 3/2003
Print ISSN: 1203-4754
Electronic ISSN: 1615-7109
DOI: https://doi.org/10.1007/s10227-002-0159-5

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Facial Lipoatrophy Following Systemic Lupus Erythematosus

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2003

Subcutaneously Administered Efalizumab (Anti-CD11a) Improves Signs and Symptoms of Moderate to Severe Plaque Psoriasis

Olmsted Syndrome—Palmoplantar and Periorificial Keratodermas: Association with Malignant Melanoma

7. Surgery and Laser

The Efficacy and Tolerability of Clobetasol Propionate Foam 0.05% in the Treatment of Mild to Moderate Plaque-type Psoriasis of Nonscalp Regions

Modulation of the Contact Hypersensitivity Response by Æ-941 (Neovastat), a Novel Antiangiogenic Agent

3. Pediatric Dermatology